原发性肝癌患者CEA、AFP、CA199和铁蛋白检测的意义

doi:10.3969/j.issn.1672-5069.2014.03.019

Abstract

Dong Xinmin, Zhang Jian, Jin Yu.. Clinical detection of serum CEA,AFP,CA199 and Ferritin in diagnosis of patients with primary liver cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 295-297.

[1] Han YF,Zhao J,Ma LY,et al. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol,2011,17（38）:4258-4270.
[2] 中华人民共和国卫生部.原发性肝癌诊疗规范（2011年版）. 临床肿瘤学杂志,2011,16（10）:929-946.
[3] 王洁,孟运运,汪茂荣. 血清AFP,GGT-Ⅱ和GCT联合检测诊断原发性肝癌的价值探讨. 实用肝脏病杂志,2012,15（6）:545-547.
[4] 李玉柱,张玉敏,寇永妹,等. 血清GGT、AFP和AFP-L3联合检测对原发性肝癌诊断的临床意义. 中国热带医学,2013,13（7）:866-868.
[5] 王强,谢跃文,夏洁. 血清TK1、AFP、CEA联合检测在原发性肝癌诊断中的临床价值. 国际检验医学杂志,2013,34（9）:1101-1102.
[6] 黄菊子,宋淼,胡秦妮,等. 血清AFP、CA199、CA50水平与原发性肝癌关系探讨. 西南国防医药,2013,23（2）:132-133.
[7] 原永明,张菁,周雪颖,等. 肝癌患者血清铁含量检测的临床意义. 检验医学,2013,28（6）:534-535.
[8] Trinchet JC,Alperovitch A,Bedossa P,et al. Epidemiology,prevention,screening and diagnosis of hepatocellular carcinoma.Bull Cancer,2009,96（1）:35-43.
[9] 黄鑫刚,史小波,郭新荣.α-L-岩藻糖苷酶联合甲胎蛋白检测在原发性肝癌诊断中的临床评价.检验医学与临床,2012,9（7）:779-780.
[10] 聂凤英,巩雅丽. 血清 AFU活性测定在早期原发性肝癌诊断中的应用价值探讨. 中国医学创新,2012,9（22）:109-110.
[11] 曾颖玲,毛惠南. 血清AFP、AKP和GGT在肝癌化疗栓塞后的改变与预后的关系. 中国热带医学,2011,11（11）:1389-1390.
[12] 王志有.原发性肝癌血清AFU、AFP、CHE及γ-GT联合检测的分析. 医学检验,2011,18（2）:74-75.
[13] 沈剑平. AFP、AFU、GCT、ALP及CA-199联合检测对肝癌的诊断价值. 国际检验医学杂志,2012,33（10）:1179-1180.
[14] 黄聪武,白岚,蔡俊杰,等. 血清铁和铁蛋白与肝病患者肝纤维化指标的关系. 第一军医大学学报,2003（23）：466-468.
[15] 程玉萍.血清铁蛋白检测在临床应用的研究进展.山西医药杂志,2013,42（6）:639-640.

Clinical detection of serum CEA,AFP,CA199 and Ferritin in diagnosis of patients with primary liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Yanni, Sun Xiaohua, He Haiyan, et al.. Preliminary study of laparoscopic hepatic portoenteral anastomosis in the treatment of neonatal with biliary atresia [J]. Journal of Practical Hepatology, 2019, 22(6): 920-923.
[2]	Wang Xiaoxiao, Chen Xinyue. Therapeutic strategy for serum HBsAg clearance in suitable population of chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 309-312.
[3]	Wang Baodan, Li Meng, Gao Yu. Predictive factors of response to interferon-α antiviral therapy in children with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 345-348.
[4]	Yuan Chunhui, Li Chunyu, Li Hongli. Efficacy of pegylated interferon α -2b in the treatment of patients with serum HBeAg positive chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 353-356.
[5]	Yuan Chunhui, Li Chunyu, Li Hongli, Zhao Hongna, Wen Wenhong, Meng Qingxu, Zhang Zhongxue. Impact of blood IL28B gene polymorphism on viralogic response in patients with HBeAg positive chronic hepatitis B receiving peginterferon alfa therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 184-187.
[6]	Wang Cuixiao, Gao Jing.. Serum Golgi protein 73, lentil lectin-reactive alpha-fetoprotein-L3,AFP andα-L- fucosidase levels in patients with primary liver cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 113-116.
[7]	Gao Xiang, Shang Shuangyan. Protective effect of Fufangbiejia, a herbal medicine, on diethylnitrosamine-induced primary liver cancer in rats and its impact on PCNA and α-SMA expression [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 553-556.
[8]	Shi Luoming, Zhou Gengfa, Sun Donglin. Prediction of response in patients with low serum HBsAg level chronic hepatitis B receiving peginterferon-α-2a after nucleos(t)ide analogues treatment [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 565-568.
[9]	Luo Dan, Chen Yong, Chen Qing, et al. Effect of pegylated interferon α-2b on peripheral blood T lymphocyte subsets and serum cytokine levels in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 200-203.
[10]	Qin Wei, Chen Yuping, Yang Zhao, et al. Expression of transforming growth factor β-1 in liver tissues of patients with primary biliary cirrhosis and its relationship with liver fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 237-240.
[11]	Tao Guoyun, Ai Lisha, Zhang Li. Prediction of sustained virologic response by surveillance of serum ribavirin concentration in chronic hepatitis C patients with genotype 1b infection receiving standardized antiviral therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 287-288.
[12]	Zhang Guobing, Xu Jianghai. Application of serum CA19-9, CA125 and CEA in diagnosis of serum AFP negative patients with intrahepatic cholangiocarcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 740-743.
[13]	Liu Liang, Liu Jinsong, He Juan. Changes of serum hypoxia inducible factor-1α and vascular endothelial growth factor levels in patients with primary liver cancer before and after TACE [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 781-782.
[14]	Xiao Xiao，He Yutong，Fang Meng，et al.. Diagnostic value of serum alpha-fetoprotein and lentil lectin-reactive alpha-fetoprotein in patients with primary liver cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 567-570.
[15]	Du Weixing, Ye Qing, Li Jinke, et al.. Changes of blood liver function index and TNF-α levels before and after treatment of patients with nonalcoholic fatty liver disease with combination therapy of DanNing tablets and simvastatin [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 490-491.